Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07ZTD
|
||||
| Former ID |
DNCL001777
|
||||
| Drug Name |
MB-07811
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] | Phase 2 | [1] | ||
| Company |
Ligand Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H32ClO5P
|
||||
| Canonical SMILES |
CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCP3(=O)OCCC(O3)<br />C4=CC(=CC=C4)Cl
|
||||
| InChI |
1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35?/m0/s1
|
||||
| InChIKey |
LGGPZDRLTDGYSQ-GYKKGXIBSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Thyroid hormone receptor beta-1 | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Thyroid hormone signaling pathway | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Hematopoietic Stem Cell Differentiation | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00879112) Study of MB07811 in Subjects With Hypercholesterolemia. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 589). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.